Physician profile
Michael G Tal
NPI 1841273661
$5,852,820.93
in general payments reported to CMS, 2019-2025
5 companies · $1.0M in 2025
The $1.0M reported for 2025 was more than what 99% of Vascular & Interventional Radiology providers received nationally (typical 2025 total: $537).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $743K · 2021: $1.0M · 2022: $897K · 2023: $826K · 2024: $1.3M · 2025: $1.0M.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $3.2M · Food and Beverage: $341.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $3,171,774.48 |
| Food and Beverage | $341.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $4,032,943.03 | 2021-2024 | Palindrome, Mahurkar |
| Mozarc Medical US LLC | $1,043,938.28 | 2025 | Palindrome |
| Covidien Lp | $742,832.86 | 2020 | |
| Bard Peripheral Vascular, INC. | $32,843.44 | 2021-2024 | Pristine, Lutonix Drug Coated Balloon |
| Becton, Dickinson and Company | $263.32 | 2025 | Powerpicc |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Tal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.